DE60324118D1 - Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression - Google Patents

Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression

Info

Publication number
DE60324118D1
DE60324118D1 DE60324118T DE60324118T DE60324118D1 DE 60324118 D1 DE60324118 D1 DE 60324118D1 DE 60324118 T DE60324118 T DE 60324118T DE 60324118 T DE60324118 T DE 60324118T DE 60324118 D1 DE60324118 D1 DE 60324118D1
Authority
DE
Germany
Prior art keywords
aed
present
gene expression
nuclear transcription
regulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324118T
Other languages
English (en)
Inventor
Roger M Loria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60324118D1 publication Critical patent/DE60324118D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60324118T 2002-03-21 2003-03-21 Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression Expired - Lifetime DE60324118D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36581702P 2002-03-21 2002-03-21
PCT/US2003/009141 WO2003080810A2 (en) 2002-03-21 2003-03-21 αAED AND βAED REGULATION OF NUCLEAR TRANSCRIPTION, GENE REGULATION, AND/OR GENE EXPRESSION

Publications (1)

Publication Number Publication Date
DE60324118D1 true DE60324118D1 (de) 2008-11-27

Family

ID=28454718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324118T Expired - Lifetime DE60324118D1 (de) 2002-03-21 2003-03-21 Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression

Country Status (7)

Country Link
US (1) US20030181434A1 (de)
EP (1) EP1490069B1 (de)
AT (1) ATE411028T1 (de)
AU (1) AU2003222070A1 (de)
CA (1) CA2483258A1 (de)
DE (1) DE60324118D1 (de)
WO (1) WO2003080810A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
SE0100857D0 (sv) * 2001-03-13 2001-03-13 Tomas Hagstroem Treatment of tumors

Also Published As

Publication number Publication date
AU2003222070A1 (en) 2003-10-08
WO2003080810A2 (en) 2003-10-02
EP1490069A4 (de) 2006-08-02
EP1490069A2 (de) 2004-12-29
EP1490069B1 (de) 2008-10-15
US20030181434A1 (en) 2003-09-25
ATE411028T1 (de) 2008-10-15
AU2003222070A8 (en) 2003-10-08
CA2483258A1 (en) 2003-10-02
WO2003080810A3 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
Hedayatpour et al. Physiological and neural adaptations to eccentric exercise: mechanisms and considerations for training
Reardon Electroceuticals spark interest
BRPI0407694A (pt) métodos de usar células derivadas do tecido adiposo no tratamento de condições cardiovasculares
WO2003105744A3 (en) THERAPEUTIC EXERCISE METHOD AND SYSTEM FOR A PARALYZED AND NON-PARALYZED NEUROMUSCULOSKLELET TRAINING SYSTEM
Wyszkowska et al. Electromagnetic fields and neurodegenerative diseases
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Xu et al. Rehabilitation effects of fatigue-controlled treadmill training after stroke: a rat model study
García-Muntión et al. Study of the mechanisms of action of the hypoalgesic effect of pressure under shock waves application: A randomised controlled trial
DE60324118D1 (de) Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression
Kaulmann et al. Stabilization of body balance with Light Touch following a mechanical perturbation: Adaption of sway and disruption of right posterior parietal cortex by cTBS
Roman Physiotherapy devices able to generate ethical dilemmas
Carlbring Single-session gamified virtual reality exposure therapy for spider phobia vs. traditional exposure therapy: A randomized-controlled non-inferiority trial with 12-month follow-up
Onose et al. Augmentation and Rehabilitation with Active Orthotic Devices
Pichiorri et al. An All-in-One BCI-supported motor imagery training station: Validation in a real clinical setting with chronic stroke patients
DENG et al. The music-motor intervention methods for speech perception and motor timing disorder of stuttering patients
García-Guadarrama et al. Design of a Portable Electric-Stimulation System to Reduce the Essential Tremor on the Hand
Linde CBT group therapy
Lew et al. Stroke and neurodegenerative disorders: 3. Poststroke rehabilitation
Raoul et al. O103/# 588 TREATMENT OF UPPER LIMB AND NECK PAIN USING PATIENT-SPECIFIC SCS PROGRAMMING AND NEURAL TARGETING CAPABILITIES: TRACK 1: SCS
Zhao et al. Nerve root magnetic stimulation: a novel stimulation mode targeting sensorimotor neural circuit to improve motor function
Hagen Is cerebellar anodal transcranial direct current stimulation an appropriate locomotor intervention for people with multiple sclerosis?
MacCulloch et al. Avoidance latencies reliably reflect sexual attitude change during aversion therapy for homosexuality
Bilanovskyi Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives
Nakajima et al. P298 Can music enhance movement intention?
Yanagisawa et al. S109 Magnetoencephalographic-based brain–machine interface robotic hand for controlling sensorimotor cortical plasticity and phantom limb pain

Legal Events

Date Code Title Description
8364 No opposition during term of opposition